Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 8 | 2024 | 56 | 1.110 |
Why?
|
| Vulvar Neoplasms | 2 | 2014 | 9 | 0.570 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 396 | 0.480 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2005 | 145 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 301 | 0.460 |
Why?
|
| Cisplatin | 4 | 2024 | 119 | 0.440 |
Why?
|
| Ovarian Neoplasms | 7 | 2009 | 130 | 0.320 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2011 | 233 | 0.300 |
Why?
|
| Carcinoma, Endometrioid | 4 | 2019 | 17 | 0.260 |
Why?
|
| Sirolimus | 2 | 2016 | 72 | 0.240 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 46 | 0.230 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 75 | 0.190 |
Why?
|
| Hysterectomy | 2 | 2017 | 70 | 0.190 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 114 | 0.190 |
Why?
|
| Female | 25 | 2024 | 30581 | 0.190 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 14 | 0.170 |
Why?
|
| Genital Neoplasms, Female | 1 | 1999 | 18 | 0.160 |
Why?
|
| Megestrol Acetate | 2 | 2016 | 3 | 0.160 |
Why?
|
| Tamoxifen | 2 | 2016 | 33 | 0.160 |
Why?
|
| Receptor, Notch2 | 1 | 2017 | 8 | 0.150 |
Why?
|
| Cervix Uteri | 1 | 1997 | 56 | 0.140 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2014 | 41 | 0.140 |
Why?
|
| Humans | 25 | 2024 | 58880 | 0.130 |
Why?
|
| Preoperative Care | 2 | 2014 | 171 | 0.130 |
Why?
|
| Middle Aged | 11 | 2024 | 16134 | 0.120 |
Why?
|
| Uterine Prolapse | 1 | 2014 | 16 | 0.120 |
Why?
|
| Endometrium | 1 | 2014 | 28 | 0.120 |
Why?
|
| Colposcopy | 1 | 2014 | 22 | 0.120 |
Why?
|
| Papillomaviridae | 1 | 2014 | 58 | 0.120 |
Why?
|
| Mass Screening | 1 | 1999 | 637 | 0.110 |
Why?
|
| Anaphylaxis | 1 | 1994 | 40 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2017 | 384 | 0.110 |
Why?
|
| Adnexal Diseases | 1 | 1993 | 8 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 123 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2013 | 112 | 0.100 |
Why?
|
| Aged | 9 | 2024 | 13221 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 139 | 0.100 |
Why?
|
| Adult | 11 | 2024 | 15609 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2013 | 262 | 0.100 |
Why?
|
| Herpes Zoster | 1 | 2011 | 23 | 0.100 |
Why?
|
| Lymphogranuloma Venereum | 1 | 1991 | 3 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2017 | 619 | 0.090 |
Why?
|
| Risk Factors | 3 | 2014 | 4975 | 0.090 |
Why?
|
| Epothilones | 1 | 2009 | 1 | 0.090 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 7 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2002 | 1446 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 22 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2009 | 176 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 5046 | 0.080 |
Why?
|
| Postoperative Complications | 3 | 2017 | 1114 | 0.070 |
Why?
|
| Mutation | 1 | 2016 | 2419 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 720 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 403 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 446 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2005 | 39 | 0.060 |
Why?
|
| Hemangiosarcoma | 1 | 2005 | 24 | 0.060 |
Why?
|
| Biopsy | 2 | 2014 | 372 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2024 | 41 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2004 | 72 | 0.060 |
Why?
|
| Neuralgia | 1 | 2003 | 20 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2024 | 3077 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 31 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2002 | 49 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 893 | 0.050 |
Why?
|
| Filgrastim | 1 | 2020 | 5 | 0.050 |
Why?
|
| Carboplatin | 1 | 2020 | 39 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 846 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 88 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 73 | 0.040 |
Why?
|
| Struma Ovarii | 1 | 1999 | 2 | 0.040 |
Why?
|
| Thyrotoxicosis | 1 | 1999 | 7 | 0.040 |
Why?
|
| Prognosis | 2 | 2002 | 1561 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 637 | 0.040 |
Why?
|
| Genetic Testing | 1 | 1999 | 132 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 1517 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 674 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2017 | 5922 | 0.040 |
Why?
|
| Ileus | 1 | 2017 | 6 | 0.040 |
Why?
|
| Laparotomy | 1 | 2017 | 45 | 0.040 |
Why?
|
| Uterine Cervical Diseases | 1 | 1997 | 4 | 0.040 |
Why?
|
| Papanicolaou Test | 1 | 1997 | 40 | 0.040 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 80 | 0.040 |
Why?
|
| Vaginal Smears | 1 | 1997 | 52 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 240 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1999 | 295 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 104 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 142 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 11 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 82 | 0.030 |
Why?
|
| Postmenopause | 1 | 1997 | 246 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 164 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 184 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 186 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 263 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 481 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1994 | 111 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 5100 | 0.030 |
Why?
|
| Ovarian Diseases | 2 | 2004 | 20 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 760 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 1993 | 12 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 1102 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 232 | 0.030 |
Why?
|
| Torsion Abnormality | 1 | 1993 | 13 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 279 | 0.030 |
Why?
|
| Ovariectomy | 1 | 1993 | 97 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 194 | 0.030 |
Why?
|
| Morbidity | 1 | 1993 | 105 | 0.030 |
Why?
|
| Ovary | 1 | 1993 | 96 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2013 | 40 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 286 | 0.030 |
Why?
|
| Carcinoma | 1 | 1993 | 115 | 0.030 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1992 | 2 | 0.030 |
Why?
|
| Forecasting | 1 | 1993 | 218 | 0.030 |
Why?
|
| Delirium | 1 | 2013 | 56 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 170 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2013 | 125 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 1992 | 30 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 447 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 711 | 0.020 |
Why?
|
| Wound Healing | 1 | 2013 | 175 | 0.020 |
Why?
|
| Herpesvirus 3, Human | 1 | 2011 | 9 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 1997 | 2316 | 0.020 |
Why?
|
| Abdominal Wall | 1 | 2011 | 20 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 59 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 139 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2011 | 37 | 0.020 |
Why?
|
| Pain Management | 1 | 2013 | 143 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 125 | 0.020 |
Why?
|
| Cohort Studies | 1 | 1997 | 2429 | 0.020 |
Why?
|
| Pelvis | 1 | 1991 | 57 | 0.020 |
Why?
|
| Physical Examination | 1 | 1991 | 103 | 0.020 |
Why?
|
| Adolescent | 3 | 2004 | 5871 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1991 | 210 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2009 | 6 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2009 | 18 | 0.020 |
Why?
|
| Taxoids | 1 | 2009 | 25 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2013 | 477 | 0.020 |
Why?
|
| Pregnancy | 2 | 1993 | 2334 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 1993 | 388 | 0.020 |
Why?
|
| Mesna | 1 | 2005 | 3 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2005 | 9 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2005 | 18 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 76 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2005 | 97 | 0.020 |
Why?
|
| Probability | 1 | 2004 | 171 | 0.010 |
Why?
|
| Fallopian Tube Diseases | 1 | 2003 | 5 | 0.010 |
Why?
|
| Child | 1 | 1993 | 4243 | 0.010 |
Why?
|
| Amitriptyline | 1 | 2003 | 8 | 0.010 |
Why?
|
| Endometriosis | 1 | 2003 | 23 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2003 | 35 | 0.010 |
Why?
|
| Abscess | 1 | 2003 | 73 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 1047 | 0.010 |
Why?
|
| Thyroglobulin | 1 | 1999 | 9 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 1999 | 26 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 116 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 1441 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 1893 | 0.010 |
Why?
|
| Cystadenoma | 1 | 1993 | 5 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1993 | 14 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1993 | 41 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1992 | 8 | 0.010 |
Why?
|
| World Health Organization | 1 | 1992 | 31 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 69 | 0.010 |
Why?
|
| Alleles | 1 | 1993 | 424 | 0.010 |
Why?
|
| Methotrexate | 1 | 1992 | 76 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1992 | 111 | 0.010 |
Why?
|
| Base Sequence | 1 | 1993 | 1309 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 1972 | 0.010 |
Why?
|
| United States | 1 | 1992 | 7441 | 0.000 |
Why?
|